BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29626519)

  • 1. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
    Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
    Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
    Ojo D; Wu Y; Bane A; Tang D
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
    Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI
    PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
    Yang S; Lee JY; Hur H; Oh JH; Kim MH
    BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
    Oh JH; Lee JY; Kim KH; Kim CY; Jeong DS; Cho Y; Nam KT; Kim MH
    Cancer Lett; 2020 Dec; 495():145-155. PubMed ID: 32987137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
    Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer.
    Merikhian P; Ghadirian R; Farahmand L; Mansouri S; Majidzadeh-A K
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):607-613. PubMed ID: 28597750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
    Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
    Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
    Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
    J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
    Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
    BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
    Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
    Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance.
    Wang L; Zhang X; Wang ZY
    Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.